 Tetrahydronaphthalenes
"Tetrahydronaphthalenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Partially saturated 1,2,3,4-tetrahydronaphthalene compounds.
| Descriptor ID |
D013764
|
| MeSH Number(s) |
D02.455.426.559.847.638.960 D04.615.638.960
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrahydronaphthalenes".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydronaphthalenes".
This graph shows the total number of publications written about "Tetrahydronaphthalenes" by people in this website by year, and whether "Tetrahydronaphthalenes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1998 | 2 | 1 | 3 | | 1999 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 0 | 2 | 2 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 1 | 2 | | 2015 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2020 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tetrahydronaphthalenes" by people in Profiles.
-
Gounder M, Ratan R, Alcindor T, Sch?ffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. Nirogacestat, a ?-Secretase Inhibitor for Desmoid Tumors. N Engl J Med. 2023 Mar 09; 388(10):898-912.
-
Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021 04 20; 39(12):1360-1370.
-
Samuels JM, Coleman JR, Moore EE, Bartley M, Vigneshwar N, Cohen M, Silliman CC, Sauaia A, Banerjee A. Alternative Complement Pathway Activation Provokes a Hypercoagulable State with Diminished Fibrinolysis. Shock. 2020 05; 53(5):560-565.
-
Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol. 2018 Mar; 25(3):768-775.
-
Klopper J, Kane M, Jimeno A, Sams S, French J, Pike L, Tompkins K, Haugen B. A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer. Thyroid. 2015 May; 25(5):563-4.
-
Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral ?-secretase inhibitor PF-03084014. Clin Cancer Res. 2015 Jan 01; 21(1):60-7.
-
Lehman AM, Montford JR, Horita H, Ostriker AC, Weiser-Evans MC, Nemenoff RA, Furgeson SB. Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cells. Mol Pharmacol. 2014 Nov; 86(5):570-9.
-
Arcaroli JJ, Quackenbush KS, Purkey A, Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song EK, Tai WM, Winn RA, Bikkavilli K, Vanscoyk M, Eckhardt SG, Messersmith WA. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a ?-secretase inhibitor, in a preclinical colorectal explant model. Br J Cancer. 2013 Aug 06; 109(3):667-75.
-
Liem-Moolenaar M, Peeters P, Kamerling IM, Hogg C, Holder G, Kleijn HJ, Spaans E, Udo De Haes J, de Kam ML, Franson KL, Cohen AF, van Gerven JM. Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men. Br J Clin Pharmacol. 2013 Jun; 75(6):1455-67.
-
Robciuc MR, Skrobuk P, Anisimov A, Olkkonen VM, Alitalo K, Eckel RH, Koistinen HA, Jauhiainen M, Ehnholm C. Angiopoietin-like 4 mediates PPAR delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubes. PLoS One. 2012; 7(10):e46212.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|